Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Novo Nordisk A/S (NVO)

139.44   0.55 (0.4%) 03-17 16:00
Open: 139.74 Pre. Close: 138.89
High: 140.28 Low: 139.1
Volume: 1,582,032 Market Cap: 313,779(M)

Technical analysis

as of: 2023-03-20 8:48:14 AM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 165.71     One year: 170.45
Support: Support1: 135.32    Support2: 112.58
Resistance: Resistance1: 141.88    Resistance2: 145.94
Pivot: 142.13
Moving Average: MA(5): 140.55     MA(20): 142.14
MA(100): 130.85     MA(250): 117.49
MACD: MACD(12,26): 0.2     Signal(9): 0.8
Stochastic oscillator: %K(14,3): 30.7     %D(3): 30.2
RSI: RSI(14): 45.7
52-week: High: 145.94  Low: 95.01
Average Vol(K): 3-Month: 1,443 (K)  10-Days: 1,792 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ NVO ] has closed above bottom band by 11.9%. Bollinger Bands are 31.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 140.48 - 141.27 141.27 - 141.99
Low: 136.98 - 138.03 138.03 - 138.99
Close: 137.94 - 139.44 139.44 - 140.82

Company Description

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Headline News

Mon, 20 Mar 2023
Novo Nordisk A/S (NVO) Up 2.27% in Premarket Trading - InvestorsObserver

Mon, 20 Mar 2023
Novo Nordisk A/S - share repurchase programme - GlobeNewswire

Sun, 19 Mar 2023
D. Scott Neal Inc. Makes New Investment in Novo Nordisk A/S ... - MarketBeat

Thu, 16 Mar 2023
Novo Nordisk Suspended From UK Trade Association For Practice Breaches - Yahoo Finance

Wed, 15 Mar 2023
Novo Nordisk A/S (NYSE:NVO) Shares Sold by Ascent Group LLC - MarketBeat

Tue, 14 Mar 2023
Novo Nordisk to slash US prices of insulin pens and vials by up to ... - Proactive Investors USA

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 2,250 (M)
Shares Float 1,610 (M)
% Held by Insiders 0 (%)
% Held by Institutions 8.5 (%)
Shares Short 1,090 (K)
Shares Short P.Month 1,710 (K)

Stock Financials

EPS 3.44
EPS Est Next Qtl 0.52
EPS Est This Year 2.42
EPS Est Next Year 2.58
Book Value (p.s.) 37.09
Profit Margin (%) 31.3
Operating Margin (%) 42.7
Return on Assets (ttm) 21.6
Return on Equity (ttm) 72
Qtrly Rev. Growth 25.5
Gross Profit (p.s.) 66
Sales Per Share 78.64
EBITDA (p.s.) 35.96
Qtrly Earnings Growth 26.3
Operating Cash Flow 78,890 (M)
Levered Free Cash Flow 57,500 (M)

Stock Valuations

PE Ratio 40.53
PEG Ratio 75.3
Price to Book value 3.75
Price to Sales 1.77
Price to Cash Flow 3.97

Stock Dividends

Dividend 0.57
Forward Dividend 0
Dividend Yield 0.4%
Dividend Pay Date 2021-08-24
Ex-Dividend Date 2021-08-15
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.